 |
|
|
|
 |
|
|
| Article 1 to 10 out of 152
|
|
-
Galapagos signs new compound management agreement
(30 Jun 2008)
Galapagos NV announces that its service division BioFocus DPI will provide compound management and related services to Sepracor Inc. Total contract value for Galapagos is EUR1 million. Under the terms of the agreement, BioFocus DPI will ......
-
OncoMethylome Sciences Signs Commercial Agreement with Laboratory Corporation of America for Colorectal Cancer Testing
(24 Jun 2008)
OncoMethylome Sciences announced that it entered into a supply agreement with Laboratory Corporation of America® Holdings (LabCorp®). OncoMethylome agreed to sell reagents to LabCorp for detecting methylation of the Vimentin DNA marker with ......
-
Galapagos announces milestone payment of EUR0.8 million in osteoarthritis alliance with GlaxoSmithKline
(17 Jun 2008)
Galapagos NV announced that it has reached two new milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering a payment of EUR0.8 million from GSK. In June 2006, GSK's Center of Excellence for ......
-
VIB and Bayer join forces for plant research
(13 Jun 2008)
The changes in our climate, producing extreme temperatures or persistent drought, have an enormous impact on our crops to put it briefly, the crops are experiencing stress. VIB has now concluded a research agreement with Bayer BioScience NV, ......
-
OncoMethylome Sciences Announces Licensing and Testing Agreement with Merck KGaA
(11 Jun 2008)
OncoMethylome's Technology to Be Used in Merck's Clinical Trial Program with Cilengitide
OncoMethylome Sciences announced that it has signed a licensing and testing agreement with Merck KGaA of Darmstadt, Germany. Under the terms of the agreement, OncoMethylome will provide MGMT gene promoter methylation testing services for ......
-
Microsurgery on the brain of the fruit fly leads to new insights into irreparable nerve injuries
(04 Jun 2008)
Every year, one million Europeans are confronted with potentially irreparable brain or spinal cord injuries resulting from traffic accidents. Because the nerves in a damaged spinal cord cannot, or cannot fully, be repaired, the patient remains ......
-
Innogenetics achieves CE mark for new human papillomavirus (HPV) genotyping test
(04 Jun 2008)
Innogenetics announced that it has received CE marking for its new and expanded HPV genotyping test, the INNO-LiPA HPV Genotyping Extra. The new generation kit allows the genotyping of 28 different HPV genotypes, of which 18 are high-risk types ......
-
Innogenetics announces definitive closure of GENimmune
(03 Jun 2008)
Innogenetics announced the final phase of its restructuring plan for the pharma division of GENimmune. In accordance with the collective labor agreement signed on May 8 with its social partners, the remaining 5 labor contracts will shortly be ......
-
OncoMethylome's Novel Test for Bladder Cancer Demonstrates Excellent Performance in Clinical Trial
(02 Jun 2008)
OncoMethylome Sciences released additional data today from an ongoing clinical verification trial of their bladder cancer test. The new data confirms the ability of this non-invasive urine-based test to accurately detect early-stage bladder ......
-
ThromboGenics Presents Further Results of the Vitreomacular Traction Trial (MIVI IIT)
(27 May 2008)
Results confirm the beneficial effects of microplasmin in patients with vitreomacular traction without need for vitrectomy throughout the 6 month follow-up period
ThromboGenics NV presented the six month follow up results from its Phase IIa MIVI IIT trial at the Euretina Congress in Vienna, Austria. The trial, which delivered positive clinical results in a number of the treated patients, was designed to ......
|
|
|
|
|
Top
